
CEFNUS DRY SYRUP Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
CEFNUS DRY SYRUP
Cefixime Oral Suspension 50mg/5ml With WFI
CEFNUS DRY SYRUP is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C. Do not freeze. Keep container tightly closed.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
CEFNUS DRY SYRUP features Cefixime Oral Suspension 50mg/5ml With WFI prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Regularly stocked across our distri for CEFNUS DRY SYRUP
CEFNUS DRY SYRUP has been regularly stocked across our district hospital formulary, supporting swift recovery and prompt restoration of standard patient routine. The protective barrier foil preserves stability and uniform product integrity over extended shelf life. Demonstrates genuine pharmaceutical excellence with reliable supply and steady commercial pull.
Questions Regarding CEFNUS DRY SYRUP
What is the therapeutic indication and composition of CEFNUS DRY SYRUP?
CEFNUS DRY SYRUP contains Cefixime Oral Suspension 50mg With WFI indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for CEFNUS DRY SYRUP?
CEFNUS DRY SYRUP is supplied in tamper-evident 100ml / 200ml PET Bottle with Graduated Measuring Cap, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for CEFNUS DRY SYRUP?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for CEFNUS DRY SYRUP along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
CEFNUS DRY SYRUP is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.





